Australia’s Starpharma and MSD (tradename of Merck & Co., Inc., Rahway, N.J., USA) have signed a research agreement allowing MSD to conduct a preclinical research evaluation of dendrimer-based antibody-drug conjugates (ADCs) utilizing Starpharma’s proprietary DEP® technology.